pyrroles has been researched along with Psoriasis in 115 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (1.74) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (4.35) | 29.6817 |
| 2010's | 96 (83.48) | 24.3611 |
| 2020's | 12 (10.43) | 2.80 |
| Authors | Studies |
|---|---|
| AlMutairi, N; Nour, T | 1 |
| Bonovas, S; Danese, S; Lasa, JS; Olivera, PA; Peyrin-Biroulet, L | 1 |
| Georgiou, S; Plachouri, KM | 1 |
| Fan, T; He, X; Huang, X; Liu, R; Ruan, Q; Su, W; Wang, T; Wu, C | 1 |
| Boehncke, WH; Graham, D; Gratacós, J; Hsu, MA; Merola, JF; Nash, P; Papp, KA; Thaçi, D; Wang, C; Wu, J; Young, P | 1 |
| Chen, Y; Gao, Q; Jiang, F; Kong, B; Li, H; Li, S; Liu, C; Liu, H; Lu, T; Ma, Y; Song, J; Wang, H; Wang, X; Xu, J; Zhang, Y; Zhong, Y; Zhu, Y; Zu, W | 1 |
| Hoff, P; Mohr, J; Mössner, R; Wilsmann-Theis, D | 1 |
| Alikhan, M; Jogi, R; Nguyen, JK; Patel, AB; Schlichte, MJ | 1 |
| Armuzzi, A; Colombel, JF; Farnier, M; Friedman, GS; Ha, C; Kwok, K; Quirk, D; Salese, L; Sands, BE; Su, C; Taub, PR | 1 |
| Dörner, T | 1 |
| Lee, YH; Song, GG | 1 |
| Gupta, P; Hutmacher, MM; Ito, K; Krishnaswami, S; Mebus, C; Papp, K; Rottinghaus, ST; Tan, H; Valdez, H; Wolk, R | 1 |
| Cernea, M; Gupta, AK; Lynde, CW | 1 |
| Elewski, B; Kaur, M; Lan, S; Merola, JF; Tallman, A; Tatulych, S | 1 |
| Ahadieh, S; Checchio, T; Gupta, P; Ito, K; Kaur, M; Krishnaswami, S; Mandema, J; Puig, L; Tallman, A; Tan, H; Valdez, H; Wolk, R | 1 |
| Chen, J; Crook, T; Gu, J; Jin, H; Lee, MG; Li, R; Liu, Q; Ports, WC; Qi, C; Tsai, TF; Tu, C; Wang, G; Zhang, J; Zheng, M; Zhu, H | 1 |
| Chen, X; Ji, S; Jin, T; Li, R; Sun, Z; Wang, Y; Zhao, Y | 1 |
| Cohen, AD; Egeberg, A; Gupta, P; Ito, K; Kaur, M; Lebwohl, M; Mallbris, L; Rottinghaus, ST; Tan, H; Tyring, SK; Valdez, H; Weinberg, JM; Winthrop, KL | 1 |
| Abe, M; Ihn, H; Isogawa, N; Ito, K; Kawaguchi, I; Kobayashi, M; Nagaoka, M; Nishigori, C; Papp, KA; Tallman, AM; Tomochika, Y; Torii, H | 1 |
| Berstein, G; Correa-da Rosa, J; Fitz, LJ; Garcet, S; Kim, J; Krueger, JG; Lee, J; Lowes, MA; Suarez-Farinas, M; Tomalin, L; Valdez, H; Wolk, R | 1 |
| Tsai, TF; Wang, TS | 1 |
| Abramovits, W; Gardner, A; Kaur, M; Korman, N; Mukwaya, G; Rottinghaus, ST; Tan, H; Valdez, H; Winthrop, KL | 1 |
| Azevedo, A; Torres, T | 1 |
| Chi, CC; Kuo, CM; Tung, TH; Wang, SH | 1 |
| Cardwell, LA; Cline, A; Feldman, SR | 1 |
| Bushmakin, AG; Cappelleri, JC; Luger, T; Mamolo, C; Ständer, S; Tallman, AM; Yosipovitch, G; Zielinski, MA | 1 |
| Chen, X; Jia, XK; Kuang, YH; Liao, LQ; Liu, YK; Lu, Y; Qin, QS; Wu, LS; Zhou, XC; Zhu, W | 1 |
| Ergun, T; Salman, A; Sarac, G | 1 |
| Pivarcsi, A; Sonkoly, E; Srivastava, A; Ståhle, M | 1 |
| Berstein, G; Fitz, L; Fraser, S; Lee, J; Mebus, CA; Quazi, A; Soderstrom, C; Valdez, H; Wolk, R; Zhang, W | 1 |
| Bakos, N; Bissonnette, R; Gardner, AC; Harper, MK; Korman, NJ; Ports, WC; Tallman, A; Tan, H; Tsai, TF; Valdez, H; Valenzuela, F | 1 |
| Gupta, P; Ito, K; Krishnaswami, S; Langley, R; Ma, G; Rottinghaus, S; Strober, B; Tallman, A; Valdez, H; Wolk, R; Xie, R | 1 |
| Berekmeri, A; Helliwell, P; Mahmood, F; Wittmann, M | 1 |
| Bachelez, H; Chouela, E; Frajzyngier, V; Gottlieb, AB; Gupta, P; Imafuku, S; Kaur, M; Puig, L; Strober, BE; Tan, H; Thaçi, D; Valdez, H; van de Kerkhof, PCM; Wolk, R | 1 |
| Armstrong, AW; Singh, S | 1 |
| Lloyd-Lavery, A | 1 |
| Baron, J; Clarysse, K; Gutermuth, J; Huth, L; Kluwig, D; Kortekaas Krohn, I; Lüscher, B; Marquardt, Y; Pfaff, CM | 1 |
| Akiyama, T; Hashimoto, T; Sakai, K; Sanders, KM; Yosipovitch, G | 1 |
| Fleming, P | 1 |
| Armstrong, AW; Connor, C; Cordoro, KM; Davis, DMR; Elewski, BE; Elmets, CA; Gelfand, JM; Gordon, KB; Gottlieb, AB; Hariharan, V; Kaplan, DH; Kavanaugh, A; Kiselica, M; Kivelevitch, D; Korman, NJ; Kroshinsky, D; Lebwohl, M; Leonardi, CL; Lichten, J; Lim, HW; Mehta, NN; Menter, A; Paller, AS; Parra, SL; Pathy, AL; Prater, EF; Rupani, RN; Siegel, M; Stoff, B; Strober, BE; Wong, EB; Wu, JJ | 1 |
| Chen, Z; Tian, F; Xu, T | 1 |
| Bushmakin, AG; Callis Duffin, K; Cappelleri, JC; Mallbris, L; Mamolo, C | 1 |
| Greiling, T; Hagstrom, E; Haynes, D; Topham, C | 1 |
| Bushmakin, AG; Cappelleri, JC; Harness, J; Mamolo, C | 1 |
| Alsina, MM; Muñoz-Santos, C; Ortiz-Ibáñez, K | 1 |
| Gordon, KB; Lingam, P; Nwe, S | 1 |
| Buonanno, M; Clark, JD; Harness, J; Kawabata, T; Langley, RG; Menter, A; Papp, K; Strober, B; Tan, H; Valdez, H; Wolk, R | 1 |
| Gadina, M; Ghoreschi, K | 1 |
| Boots, AMH; He, X; Joosten, I; Keijsers, R; Koenen, HJPM; Koerber, A; Smeets, RL; van de Kerkhof, PC; van Rijssen, E | 1 |
| Bushmakin, AG; Cappelleri, JC; Mamolo, C; Stewart, M | 1 |
| Kato, Y; Yamamoto, T | 1 |
| Buonanno, M; Menter, A; Papp, KA; Tan, H; Tyring, S; Wolk, R | 1 |
| Bushmakin, AG; Cappelleri, JC; Mamolo, CM | 1 |
| Han, G | 1 |
| Armstrong, AW; Hsu, L | 1 |
| Craiglow, BG; King, BA | 1 |
| Huang, XR; Lan, HY; Meng, XM; Wang, XJ; Yang, L; Zhang, Y | 1 |
| Leonardi, CL; Sobell, JM | 1 |
| Kanwar, AJ; Kaul, D; Parsad, D; Soodgupta, D | 1 |
| Foley, P; Kelly, JB; Strober, BE | 1 |
| Bachinsky, M; Bissonnette, R; Foley, P; Griffiths, CE; Gupta, P; Iversen, L; Mallbris, L; Proulx, J; Romiti, R; Rottinghaus, ST; Sofen, H; Tan, H; Valdez, H; Wolk, R | 1 |
| Mirmirani, P | 1 |
| Bianchi, L; Buonomo, O; Chimenti, MS; Chimenti, S; Chiricozzi, A; Faleri, S; Saraceno, R | 1 |
| Husstedt, IW; Luger, TA; Ständer, S; Tsianakas, A; von Köckritz, A; Zeidler, C | 1 |
| Goldenberg, G; Mansouri, Y | 1 |
| Buonanno, M; Papp, KA; Pariser, D; Tan, H; Tyring, SK; Valdez, H; Valenzuela, F; Wang, J; Wolk, R | 1 |
| Alinia, H; Feldman, SR | 1 |
| Lebwohl, M | 1 |
| Bachelez, H; Chimenti, S; Gupta, P; Kubanov, A; Lee, JH; Papacharalambous, J; Proulx, J; Strohal, R; Tan, H; Tawadrous, M; Valdez, H; Valenzuela, F; van de Kerkhof, PC; Wolk, R; Yakusevich, V | 1 |
| Abe, M; Buonanno, M; Elewski, B; Feldman, SR; Gottlieb, AB; Gupta, P; Lan, S; Langley, R; Luger, T; Menter, MA; Papp, KA; Proulx, J; Thaci, D; Wolk, R | 1 |
| Bissonnette, R; Feldman, SR; Gupta, P; Johnson, TR; Ports, WC; Tan, H | 1 |
| Koo, J; Levin, E; McAndrew, R | 1 |
| Cantrell, W; Elewski, BE; Seminario-Vidal, L | 1 |
| Asahina, A; Etoh, T; Igarashi, A; Imafuku, S; Nagaoka, M; Ohtsuki, M; Saeki, H; Shibasaki, Y; Tomochika, Y; Toyoizumi, S | 1 |
| Bardazzi, F; Di Lernia, V | 1 |
| Feldman, SR; Gardner, A; Gupta, P; Krueger, JG; Langley, RG; Luo, Y; Mallbris, L; Mebus, C; Papp, KA; Tan, H; Tatulych, S; Thaci, D; Torii, H; Tyring, S; Wolk, R | 1 |
| Warren, RB; Yiu, ZZ | 1 |
| Clark, JD; Cueto, I; Fuentes-Duculan, J; Krueger, J; O'Neil, SP; Reddy, PS; Rottinghaus, ST; Suárez-Fariñas, M; Tan, H; Tatulych, S; Valdez, H; von Schack, D; Wang, CQ; Whitley, MZ; Wolk, R | 1 |
| Amaya-Guerra, M; Cather, J; Gupta, P; Kaszuba, A; Krueger, JG; Leonardi, C; Mallbris, L; Menter, MA; Nadashkevich, O; Papp, KA; Pariser, DM; Tan, H; Tatulych, S; Tsai, TF; Valdez, H; Wohlrab, J | 1 |
| Bianchi, L; Chimenti, S; D'Adamio, S; Galluzzo, M; Servoli, S; Talamonti, M | 1 |
| Mallbris, L; Mamolo, C; Papacharalambous, J; Paul, C; Tan, H; Valdez, H; Valenzuela, F | 1 |
| Chen, Y; Clowse, ME; Feldman, SR; Frazier, D; Geier, J; Isaacs, JD; Kimball, AB; Marren, A; Proulx, J; Strand, V; Warren, RB; Xibillé, D | 1 |
| Ahlehoff, O; Egeberg, A; Hansen, PR; Qureshi, AA; Robertson, D; Strober, BE; Tan, H; Valdez, H; Wolk, R; Wu, JJ | 1 |
| Leonardi, CL | 1 |
| Kerdel, FA | 1 |
| Gordon, K; Griffins, CE; Mrowietz, U; Tallman, A; Tan, H; Valdez, H; Wolk, R | 1 |
| Bachinsky, M; Griffiths, CE; Kircik, L; Mallbris, L; Mamolo, C; Rottinghaus, ST; Sofen, H; Tan, H; Vender, R | 1 |
| Augustin, M; Buonanno, M; de la Cruz, C; Feldman, SR; Gooderham, M; Kaur, M; Lan, S; Mallbris, L; Mamolo, C; Tatulych, S; Thaçi, D; Valdez, H | 1 |
| Bissonnette, R; Draelos, Z; Feldman, SR; Gooderham, M; Iversen, L; Mamolo, C; Papp, KA; Ports, WC; Purohit, V; Soung, J; Wang, C | 1 |
| Fukui, S; Horai, Y; Ichinose, K; Iwamoto, N; Kawakami, A; Kawashiri, SY; Koga, T; Nakamura, H; Sato, T; Umeda, M | 1 |
| Braun, J | 1 |
| Ahmad Nasrollahi, S; Firooz, A; Hashemi, A; Nassiri Kashani, M; Samadi, A | 1 |
| Ceovic, R; Gulin, SJ; Kostovic, K; Mokos, ZB | 1 |
| Bagherani, N; Smoller, BR | 1 |
| Damsky, W; King, BA | 1 |
| Ramot, Y; Shreberk-Hassidim, R; Zlotogorski, A | 1 |
| Boy, MG; Chan, G; Changelian, PS; Chow, VF; Clucas, AT; Gaweco, AS; Krueger, JG; Wang, C; Wilkinson, BE; Zwillich, SH | 1 |
| Dudek, AZ; Franklin, M; Murthaiah, PK; Truskinovsky, AM | 1 |
| West, K | 1 |
| Manicassamy, S | 1 |
| Fournier, C; Tisman, G | 1 |
| Agarwal, N; Batten, J; Callis-Duffin, K; Narayanan, S | 1 |
| Perlamutrov, IuN; Shkol'nik, EL; Shkol'nik, MN; Vasiuk, IuA | 1 |
| Albert, R; Beerli, C; Cooke, NG; Cottens, S; Evenou, JP; Faller, B; Jean, C; Sedrani, R; von Matt, P; Wagner, J; Weckbecker, G; Wiegand, H; Zenke, G | 1 |
| Ehsani, AH; Faghihi, T; Mehrabian, Z; Radfar, M; Rezaei Hemami, M | 1 |
| Altman, A; Kong, KF | 1 |
| Dabade, TS; Feldman, SR; Gustafson, CJ; Kwatra, SG | 1 |
| Buonanno, M; Gupta, P; Harness, JA; Krishnaswami, S; Langley, RG; Menter, A; Papp, KA; Strober, B; Tan, H; Wolk, R | 1 |
| Crow, JM | 1 |
| Harness, J; Mamolo, C; Menter, A; Tan, H | 1 |
| Bissonnette, R; Bolduc, C; Khan, S; Lamba, M; Lan, S; Papp, K; Ports, WC | 1 |
| Dudek, AZ; Keshtgarpour, M | 1 |
| Forsberg, S; Ostman, A; Rollman, O | 1 |
| Nuwer, DC | 1 |
| Swanbeck, G | 1 |
34 review(s) available for pyrroles and Psoriasis
| Article | Year |
|---|---|
Safety of Janus Kinase Inhibitors in Patients With Inflammatory Bowel Diseases or Other Immune-mediated Diseases: A Systematic Review and Meta-Analysis.
Topics: Arthritis, Rheumatoid; Azetidines; Herpes Zoster; Heterocyclic Compounds, 3-Ring; Humans; Incidence; Inflammatory Bowel Diseases; Janus Kinase Inhibitors; Janus Kinases; Piperidines; Placebos; Psoriasis; Purines; Pyrazoles; Pyridines; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Spondylitis, Ankylosing; Sulfonamides; Survival Analysis; Treatment Outcome; Triazoles | 2020 |
JAK inhibitors in chronic plaque psoriasis: What is known so far.
Topics: Adamantane; Azetidines; Humans; Janus Kinase Inhibitors; Janus Kinases; Niacinamide; Nitriles; Piperidines; Prospective Studies; Psoriasis; Purines; Pyrazoles; Pyridines; Pyrimidines; Pyrroles; Sulfonamides; Triazoles | 2020 |
A case of new-onset vitiligo in a patient on tofacitinib and brief review of paradoxical presentations with other novel targeted therapies.
Topics: Adult; Arthritis, Rheumatoid; Female; Hidradenitis Suppurativa; Humans; Janus Kinase Inhibitors; Keratoacanthoma; Melanoma; Piperidines; Programmed Cell Death 1 Receptor; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Psoriasis; Pyrimidines; Pyrroles; Tumor Necrosis Factor-alpha; Vitiligo | 2020 |
Relative efficacy and safety of tofacitinib for treating psoriasis: A Bayesian network meta-analysis of randomized controlled trials.
Topics: Humans; Network Meta-Analysis; Piperidines; Psoriasis; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Treatment Outcome | 2021 |
Tofacitinib in the Treatment of Rheumatoid Arthritis and Chronic Plaque Psoriasis.
Topics: Arthritis, Rheumatoid; Clinical Trials, Phase III as Topic; Humans; Janus Kinase 3; Piperidines; Protein Kinase Inhibitors; Psoriasis; Pyrimidines; Pyrroles; Treatment Outcome | 2017 |
Quantitative Evaluations of Time-Course and Treatment Effects of Systemic Agents for Psoriasis: A Model-Based Meta-Analysis.
Topics: Dose-Response Relationship, Drug; Humans; Models, Statistical; Piperidines; Protein Kinase Inhibitors; Psoriasis; Pyrimidines; Pyrroles; Severity of Illness Index; Time Factors; Treatment Outcome | 2017 |
Tofacitinib in psoriatic arthritis.
Topics: Animals; Arthritis, Psoriatic; Clinical Trials as Topic; Humans; Janus Kinases; Piperidines; Protein Kinase Inhibitors; Psoriasis; Pyrimidines; Pyrroles | 2017 |
Tofacitinib: A New Oral Therapy for Psoriasis.
Topics: Administration, Oral; Clinical Trials as Topic; Humans; Janus Kinases; Piperidines; Protein Kinase Inhibitors; Psoriasis; Pyrimidines; Pyrroles | 2018 |
Efficacy and safety of tofacitinib for moderate-to-severe plaque psoriasis: a systematic review and meta-analysis of randomized controlled trials.
Topics: Dermatologic Agents; Humans; Janus Kinase Inhibitors; Piperidines; Placebos; Psoriasis; Pyrimidines; Pyrroles; Quality of Life; Randomized Controlled Trials as Topic; Severity of Illness Index; Treatment Outcome | 2018 |
Advances in treating psoriasis in the elderly with small molecule inhibitors.
Topics: Adamantane; Azetidines; Clinical Trials as Topic; Humans; Niacinamide; Nitriles; Phosphodiesterase 4 Inhibitors; Piperidines; Psoriasis; Purines; Pyrazoles; Pyrimidines; Pyrroles; Severity of Illness Index; Small Molecule Libraries; Sulfonamides; Thalidomide | 2017 |
Alopecia universalis unresponsive to treatment with tofacinitib: report of a case with a brief review of the literature.
Topics: Alopecia Areata; Humans; Janus Kinase Inhibitors; Male; Piperidines; Psoriasis; Pyrimidines; Pyrroles; Treatment Failure; Young Adult | 2017 |
Tofacitinib for the treatment of psoriasis and psoriatic arthritis.
Topics: Antirheumatic Agents; Arthritis, Psoriatic; Clinical Trials as Topic; Drug Approval; Humans; Janus Kinases; Nasopharyngitis; Piperidines; Protein Kinase Inhibitors; Psoriasis; Pyrimidines; Pyrroles | 2018 |
Oral small molecules for psoriasis.
Topics: Administration, Oral; Anti-Inflammatory Agents, Non-Steroidal; Humans; Patient Selection; Piperidines; Protein Kinase Inhibitors; Psoriasis; Pyrimidines; Pyrroles; Thalidomide; Thiazoles | 2018 |
Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics.
Topics: Adalimumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Biological Products; Biosimilar Pharmaceuticals; Certolizumab Pegol; Dermatologic Agents; Drug Therapy, Combination; Etanercept; Evidence-Based Medicine; Humans; Infliximab; Piperidines; Psoriasis; Pyrimidines; Pyrroles; Ustekinumab | 2019 |
Efficacy and safety of tofacitinib for the treatment of chronic plaque psoriasis: a systematic review and meta-analysis.
Topics: Chronic Disease; Humans; Piperidines; Protein Kinase Inhibitors; Psoriasis; Pyrimidines; Pyrroles; Treatment Outcome | 2019 |
Jakpot! New small molecules in autoimmune and inflammatory diseases.
Topics: Animals; Autoimmune Diseases; Cytokines; Humans; Immunosuppressive Agents; Inflammation; Janus Kinases; Mice; Nitriles; Piperidines; Protein Kinase Inhibitors; Psoriasis; Pyrazoles; Pyrimidines; Pyrroles; Signal Transduction | 2014 |
In the pipeline for psoriasis: upcoming psoriasis treatments.
Topics: Adalimumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Arthritis, Psoriatic; Certolizumab Pegol; Etanercept; Humans; Immunoglobulin Fab Fragments; Immunoglobulin G; Immunosuppressive Agents; Infliximab; Interleukin-12 Subunit p40; Janus Kinases; Nitriles; Piperidines; Polyethylene Glycols; Protein Kinase Inhibitors; Psoriasis; Pyrazoles; Pyrimidines; Pyrroles; Receptors, Interleukin-17; Receptors, Tumor Necrosis Factor; Tumor Necrosis Factor-alpha; Ustekinumab | 2014 |
JAK inhibitors: treatment efficacy and safety profile in patients with psoriasis.
Topics: Clinical Trials as Topic; Gene Expression Regulation; Humans; Janus Kinase 1; Janus Kinase 2; Janus Kinase 3; Molecular Targeted Therapy; Nitriles; Piperidines; Protein Kinase Inhibitors; Psoriasis; Pyrazoles; Pyrimidines; Pyrroles; Signal Transduction; Treatment Outcome | 2014 |
Therapeutic development in psoriasis.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Clinical Trials as Topic; Humans; Immunologic Factors; Interleukin-23; Phosphodiesterase Inhibitors; Piperidines; Protein Kinase Inhibitors; Psoriasis; Pyrimidines; Pyrroles; Thalidomide; Treatment Outcome | 2014 |
Current and future oral systemic therapies for psoriasis.
Topics: Acitretin; Anti-Inflammatory Agents, Non-Steroidal; Antimetabolites; Cyclosporine; Fumarates; Humans; Hydroxyurea; Immunosuppressive Agents; Isoxazoles; Keratolytic Agents; Leflunomide; Methotrexate; Mycophenolic Acid; Piperidines; Protein Kinase Inhibitors; Psoriasis; Pyrimidines; Pyrroles; Sulfasalazine; Thalidomide; Thioguanine | 2015 |
Tofacitinib for the treatment of moderate-to-severe psoriasis.
Topics: Animals; Clinical Trials as Topic; Disease Progression; Humans; Janus Kinases; Molecular Targeted Therapy; Piperidines; Protein Kinase Inhibitors; Psoriasis; Pyrimidines; Pyrroles; STAT Transcription Factors | 2015 |
New systemic therapies for psoriasis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Biological Factors; Humans; Piperidines; Protein Kinase Inhibitors; Psoriasis; Pyrimidines; Pyrroles; Thalidomide | 2015 |
Emerging Oral Immunomodulators for the Treatment of Psoriasis: A Review of Phase III Clinical Trials for Apremilast and Tofacitinib.
Topics: Administration, Oral; Clinical Trials, Phase III as Topic; Humans; Immunologic Factors; Phosphodiesterase 4 Inhibitors; Piperidines; Protein Kinase Inhibitors; Psoriasis; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Severity of Illness Index; Thalidomide | 2015 |
Profile of tofacitinib citrate and its potential in the treatment of moderate-to-severe chronic plaque psoriasis.
Topics: Chronic Disease; Clinical Trials as Topic; Humans; Janus Kinase 3; Piperidines; Protein Kinase Inhibitors; Psoriasis; Pyrimidines; Pyrroles | 2016 |
Novel Oral Therapies for Psoriasis and Psoriatic Arthritis.
Topics: Adamantane; Adenosine; Adenosine A3 Receptor Antagonists; Administration, Oral; Arthritis, Psoriatic; Azetidines; Biological Factors; Biological Therapy; Clinical Trials as Topic; Humans; Isonicotinic Acids; Janus Kinases; Niacinamide; Phosphodiesterase 4 Inhibitors; Piperidines; Protein Kinase Inhibitors; Psoriasis; Purines; Pyrazoles; Pyrimidines; Pyrroles; Receptors, Lysosphingolipid; rho-Associated Kinases; Sulfonamides; Thalidomide; Thiazoles | 2016 |
Tofacitinib for the treatment of psoriasis.
Topics: Biomarkers; Drug Administration Schedule; Humans; Piperidines; Protein Kinase Inhibitors; Psoriasis; Pyrimidines; Pyrroles | 2016 |
New targets in psoriatic arthritis.
Topics: Adalimumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Psoriatic; Cyclophosphamide; Etanercept; Humans; Infliximab; Methotrexate; Molecular Targeted Therapy; Phosphodiesterase 4 Inhibitors; Piperidines; Psoriasis; Pyrimidines; Pyrroles; Sulfasalazine; Thalidomide; Ustekinumab | 2016 |
Janus kinase (JAK) inhibitors for the treatment of skin and hair disorders: a review of literature.
Topics: Alopecia Areata; Azetidines; Dermatitis, Atopic; Humans; Janus Kinase Inhibitors; Janus Kinases; Nitriles; Piperidines; Psoriasis; Purines; Pyrazoles; Pyrimidines; Pyrroles; Skin Diseases; Sulfonamides; Vitiligo | 2017 |
Tofacitinib, an Oral Janus Kinase Inhibitor: Perspectives in Dermatology.
Topics: Administration, Oral; Alopecia Areata; Dermatitis, Atopic; Humans; Janus Kinases; Piperidines; Protein Kinase Inhibitors; Psoriasis; Pyrimidines; Pyrroles; Signal Transduction; Skin Diseases; Vitiligo | 2017 |
JAK inhibitors in dermatology: The promise of a new drug class.
Topics: Alopecia Areata; Anti-Inflammatory Agents; Azetidines; Clinical Trials as Topic; Dermatitis, Atopic; Dermatologic Agents; Humans; Janus Kinases; Molecular Targeted Therapy; Nitriles; Piperidines; Protein Kinase Inhibitors; Psoriasis; Purines; Pyrazoles; Pyrimidines; Pyrroles; Signal Transduction; Skin Diseases; Sulfonamides; Vitiligo | 2017 |
Janus kinase inhibitors in dermatology: A systematic review.
Topics: Alopecia Areata; Anti-Inflammatory Agents; Antineoplastic Agents; Azetidines; Dermatologic Agents; Drug Eruptions; Humans; Janus Kinases; Molecular Targeted Therapy; Nitriles; Piperidines; Protein Kinase Inhibitors; Psoriasis; Purines; Pyrazoles; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Signal Transduction; Skin Diseases; Sulfonamides | 2017 |
CP-690550, a JAK3 inhibitor as an immunosuppressant for the treatment of rheumatoid arthritis, transplant rejection, psoriasis and other immune-mediated disorders.
Topics: Animals; Arthritis, Rheumatoid; Clinical Trials as Topic; Drug Evaluation, Preclinical; Graft Rejection; Humans; Immunosuppressive Agents; Janus Kinase 3; Piperidines; Protein Kinase Inhibitors; Psoriasis; Pyrimidines; Pyrroles | 2009 |
Sotrastaurin, a protein kinase C inhibitor for the prevention of transplant rejection and treatment of psoriasis.
Topics: Animals; Clinical Trials as Topic; Graft Rejection; Humans; Organ Transplantation; Protein Kinase C; Protein Kinase Inhibitors; Psoriasis; Pyrroles; Quinazolines | 2009 |
JAK inhibitors in psoriasis: a promising new treatment modality.
Topics: Animals; Cytokines; Humans; Janus Kinases; Nitriles; Piperidines; Psoriasis; Pyrazoles; Pyrimidines; Pyrroles; Severity of Illness Index | 2012 |
33 trial(s) available for pyrroles and Psoriasis
| Article | Year |
|---|---|
Evaluating Dosage Optimality for Tofacitinib, an Oral Janus Kinase Inhibitor, in Plaque Psoriasis, and the Influence of Body Weight.
Topics: Administration, Oral; Body Weight; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Janus Kinase Inhibitors; Male; Middle Aged; Models, Biological; Piperidines; Psoriasis; Pyrimidines; Pyrroles; Treatment Outcome | 2017 |
Efficacy of tofacitinib for the treatment of nail psoriasis: Two 52-week, randomized, controlled phase 3 studies in patients with moderate-to-severe plaque psoriasis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Double-Blind Method; Female; Humans; Male; Middle Aged; Nail Diseases; Piperidines; Protein Kinase Inhibitors; Psoriasis; Pyrimidines; Pyrroles; Time Factors; Treatment Outcome; Young Adult | 2017 |
The efficacy and safety of tofacitinib in Asian patients with moderate to severe chronic plaque psoriasis: A Phase 3, randomized, double-blind, placebo-controlled study.
Topics: Administration, Oral; Adult; Asian People; China; Double-Blind Method; Female; Humans; Janus Kinases; Male; Middle Aged; Piperidines; Protein Kinase Inhibitors; Psoriasis; Pyrimidines; Pyrroles; Republic of Korea; Severity of Illness Index; Taiwan; Treatment Outcome | 2017 |
Serum Human Beta-Defensin-2 Is a Possible Biomarker for Monitoring Response to JAK Inhibitor in Psoriasis Patients.
Topics: Adult; Aged; beta-Defensins; Biomarkers; Female; Humans; Janus Kinases; Male; Middle Aged; Piperidines; Protein Kinase Inhibitors; Psoriasis; Pyrimidines; Pyrroles; ROC Curve; Severity of Illness Index | 2017 |
Tofacitinib for the treatment of moderate to severe chronic plaque psoriasis in Japanese patients: Subgroup analyses from a randomized, placebo-controlled phase 3 trial.
Topics: Adult; Female; Humans; Male; Middle Aged; Piperidines; Protein Kinase Inhibitors; Psoriasis; Pyrimidines; Pyrroles | 2017 |
Reduction of Inflammatory and Cardiovascular Proteins in the Blood of Patients with Psoriasis: Differential Responses between Tofacitinib and Etanercept after 4 Weeks of Treatment.
Topics: Adult; Aged; Cardiovascular Diseases; Cytokines; Etanercept; Female; Humans; Inflammation; Male; Middle Aged; Piperidines; Protein Kinase Inhibitors; Proteomics; Psoriasis; Pyrimidines; Pyrroles; Risk Factors; Treatment Outcome; Young Adult | 2018 |
Association between serum interleukin-17A and clinical response to tofacitinib and etanercept in moderate to severe psoriasis.
Topics: Double-Blind Method; Etanercept; Female; Humans; Immunosuppressive Agents; Interleukin-17; Linear Models; Male; Piperidines; Protein Kinase Inhibitors; Psoriasis; Pyrimidines; Pyrroles; Remission Induction; Severity of Illness Index; Tumor Necrosis Factor-alpha | 2018 |
Tofacitinib in patients with moderate-to-severe chronic plaque psoriasis: long-term safety and efficacy in an open-label extension study.
Topics: Administration, Oral; Adult; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Female; Follow-Up Studies; Humans; Janus Kinase 3; Male; Middle Aged; Piperidines; Protein Kinase Inhibitors; Psoriasis; Pyrimidines; Pyrroles; Severity of Illness Index; Time Factors; Treatment Outcome | 2018 |
Psychometric validation of the physician global assessment scale for assessing severity of psoriasis disease activity.
Topics: Double-Blind Method; Factor Analysis, Statistical; Humans; Pain Measurement; Physicians; Piperidines; Protein Kinase Inhibitors; Psoriasis; Psychometrics; Pyrimidines; Pyrroles; Quality of Life; Reproducibility of Results; Severity of Illness Index | 2013 |
Effect of tofacitinib, a Janus kinase inhibitor, on haematological parameters during 12 weeks of psoriasis treatment.
Topics: Adolescent; Adult; Aged; Basophils; Blood Cell Count; Chronic Disease; Dermatologic Agents; Dose-Response Relationship, Drug; Female; Hematocrit; Hemoglobins; Humans; Killer Cells, Natural; Leukocytes; Male; Middle Aged; Monocytes; Piperidines; Protein Kinase Inhibitors; Psoriasis; Pyrimidines; Pyrroles; Young Adult | 2013 |
The relationship between pruritus and the clinical signs of psoriasis in patients receiving tofacitinib.
Topics: Adult; Double-Blind Method; Female; Humans; Male; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pruritus; Psoriasis; Psychometrics; Pyrimidines; Pyrroles; Reproducibility of Results; Treatment Outcome | 2015 |
Efficacy of tofacitinib, an oral janus kinase inhibitor, on clinical signs of moderate-to-severe plaque psoriasis in different body regions.
Topics: Administration, Oral; Dose-Response Relationship, Drug; Double-Blind Method; Humans; Janus Kinases; Piperidines; Protein Kinase Inhibitors; Psoriasis; Pyrimidines; Pyrroles; Severity of Illness Index; Treatment Outcome | 2014 |
Application of the Itch Severity Score in patients with moderate-to-severe plaque psoriasis: Clinically important difference and responder analyses.
Topics: Double-Blind Method; Humans; Piperidines; Pruritus; Psoriasis; Pyrimidines; Pyrroles; Treatment Outcome | 2015 |
Tofacitinib withdrawal and retreatment in moderate-to-severe chronic plaque psoriasis: a randomized controlled trial.
Topics: Adolescent; Adult; Aged; Chronic Disease; Dermatologic Agents; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Patient Outcome Assessment; Piperidines; Protein Kinase Inhibitors; Psoriasis; Pyrimidines; Pyrroles; Quality of Life; Retreatment; Treatment Outcome; Young Adult | 2015 |
Effects of tofacitinib on lymphocyte sub-populations, CMV and EBV viral load in patients with plaque psoriasis.
Topics: Adult; C-Reactive Protein; Cytomegalovirus; DNA, Viral; Dose-Response Relationship, Drug; Female; Herpesvirus 4, Human; Humans; Lymphocyte Count; Lymphocyte Subsets; Male; Middle Aged; Piperidines; Protein Kinase Inhibitors; Psoriasis; Pyrimidines; Pyrroles; Viral Load | 2015 |
Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Chronic Disease; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Etanercept; Female; Humans; Immunoglobulin G; Male; Middle Aged; Piperidines; Protein Kinase Inhibitors; Psoriasis; Pyrimidines; Pyrroles; Receptors, Tumor Necrosis Factor; Treatment Outcome | 2015 |
Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials.
Topics: Administration, Oral; Adolescent; Adult; Aged; Chronic Disease; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Piperidines; Protein Kinase Inhibitors; Psoriasis; Pyrimidines; Pyrroles; Treatment Outcome; Young Adult | 2015 |
Randomized Pilot Clinical Trial of Tofacitinib Solution for Plaque Psoriasis: Challenges of the Intra-Subject Study Design.
Topics: Adult; Aged; Female; Humans; Male; Medication Adherence; Middle Aged; Pilot Projects; Piperidines; Protein Kinase Inhibitors; Psoriasis; Pyrimidines; Pyrroles; Research Design; Self Care; Severity of Illness Index | 2015 |
Oral tofacitinib efficacy, safety and tolerability in Japanese patients with moderate to severe plaque psoriasis and psoriatic arthritis: A randomized, double-blind, phase 3 study.
Topics: Administration, Oral; Adult; Aged; Arthritis, Psoriatic; Double-Blind Method; Female; Herpes Zoster; Humans; Japan; Male; Middle Aged; Piperidines; Protein Kinase Inhibitors; Psoriasis; Pyrimidines; Pyrroles; Treatment Outcome | 2016 |
Tofacitinib attenuates pathologic immune pathways in patients with psoriasis: A randomized phase 2 study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Biomarkers; Biopsy; Double-Blind Method; Drug Administration Schedule; Female; Humans; Keratinocytes; Male; Middle Aged; Piperidines; Protein Kinase Inhibitors; Psoriasis; Pyrimidines; Pyrroles; Signal Transduction; Skin; Treatment Outcome; Young Adult | 2016 |
Efficacy of Tofacitinib for the Treatment of Moderate-to-Severe Chronic Plaque Psoriasis in Patient Subgroups from Two Randomised Phase 3 Trials.
Topics: Aged; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Piperidines; Protein Kinase Inhibitors; Psoriasis; Pyrimidines; Pyrroles; Severity of Illness Index; Treatment Outcome | 2016 |
Tofacitinib versus etanercept or placebo in patients with moderate to severe chronic plaque psoriasis: patient-reported outcomes from a Phase 3 study.
Topics: Chronic Disease; Dermatologic Agents; Etanercept; Humans; Patient Satisfaction; Piperidines; Placebos; Psoriasis; Pyrimidines; Pyrroles; Treatment Outcome | 2016 |
Early clinical response to tofacitinib treatment as a predictor of subsequent efficacy: Results from two phase 3 studies of patients with moderate-to-severe plaque psoriasis.
Topics: Administration, Oral; Double-Blind Method; Female; Humans; Male; Middle Aged; Piperidines; Psoriasis; Pyrimidines; Pyrroles; ROC Curve; Severity of Illness Index; Treatment Outcome | 2017 |
Effect of tofacitinib withdrawal and re-treatment on patient-reported outcomes: results from a Phase 3 study in patients with moderate to severe chronic plaque psoriasis.
Topics: Chronic Disease; Dermatologic Agents; Double-Blind Method; Humans; Piperidines; Psoriasis; Pyrimidines; Pyrroles; Quality of Life; Severity of Illness Index | 2017 |
Tofacitinib improves pruritus and health-related quality of life up to 52 weeks: Results from 2 randomized phase III trials in patients with moderate to severe plaque psoriasis.
Topics: Adult; Female; Humans; Male; Middle Aged; Pain; Patient Satisfaction; Piperidines; Protein Kinase Inhibitors; Pruritus; Psoriasis; Pyrimidines; Pyrroles; Quality of Life; Severity of Illness Index | 2016 |
Treatment of plaque psoriasis with an ointment formulation of the Janus kinase inhibitor, tofacitinib: a Phase 2b randomized clinical trial.
Topics: Adult; Aged; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Janus Kinases; Male; Middle Aged; Ointments; Piperidines; Protein Kinase Inhibitors; Psoriasis; Pyrimidines; Pyrroles; Young Adult | 2016 |
Efficacy of topical tofacitinib, a Janus kinase inhibitor, in the treatment of plaque psoriasis.
Topics: Administration, Cutaneous; Dermatologic Agents; Humans; Janus Kinase Inhibitors; Piperidines; Psoriasis; Pyrimidines; Pyrroles; Treatment Outcome | 2017 |
Double-blind, placebo-controlled, dose-escalation study to evaluate the pharmacologic effect of CP-690,550 in patients with psoriasis.
Topics: Adult; Biopsy; Dose-Response Relationship, Drug; Double-Blind Method; Humans; Middle Aged; Piperidines; Psoriasis; Pyrimidines; Pyrroles | 2009 |
[Possibilities of atorvastatin in complex management of extensive psoriasis in patients with arterial hypertension].
Topics: Atorvastatin; Blood Pressure; Dose-Response Relationship, Drug; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Male; Middle Aged; Psoriasis; Pyrroles; Quality of Life; Severity of Illness Index; Skin; Treatment Outcome | 2010 |
Atorvastatin for the treatment of plaque-type psoriasis.
Topics: Administration, Oral; Adolescent; Adult; Atorvastatin; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Iran; Male; Middle Aged; Prospective Studies; Psoriasis; Pyrroles; Severity of Illness Index; Treatment Outcome; Young Adult | 2011 |
Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study.
Topics: Administration, Oral; Adult; Chronic Disease; Dermatologic Agents; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Janus Kinase 3; Male; Piperidines; Psoriasis; Pyrimidines; Pyrroles; Treatment Outcome | 2012 |
Tofacitinib (CP-690,550), an oral Janus kinase inhibitor, improves patient-reported outcomes in a phase 2b, randomized, double-blind, placebo-controlled study in patients with moderate-to-severe psoriasis.
Topics: Adult; Double-Blind Method; Female; Humans; Janus Kinase 3; Male; Middle Aged; Patient Outcome Assessment; Patient Satisfaction; Piperidines; Protein Kinase Inhibitors; Psoriasis; Pyrimidines; Pyrroles; Quality of Life; Severity of Illness Index; Surveys and Questionnaires | 2014 |
A randomized phase 2a efficacy and safety trial of the topical Janus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis.
Topics: Administration, Cutaneous; Adult; Aged; Chronic Disease; Dermatologic Agents; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Ointments; Piperidines; Protein Kinase Inhibitors; Psoriasis; Pyrimidines; Pyrroles; Treatment Outcome; Young Adult | 2013 |
48 other study(ies) available for pyrroles and Psoriasis
| Article | Year |
|---|---|
Tofacitinib in Pediatric Psoriasis: An Open-Label Trial to Study Its Safety and Efficacy in Children.
Topics: Adolescent; Child; Female; Humans; Male; Piperidines; Protein Kinase Inhibitors; Psoriasis; Pyrimidines; Pyrroles; Treatment Outcome | 2020 |
Treating Autoimmune Diseases by Targeting IL-23 with Gene-Silencing Pyrrole-Imidazole Polyamide.
Topics: Animals; Autoimmune Diseases; Female; Gene Silencing; Imidazoles; Imiquimod; Interleukin-23 Subunit p19; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Molecular Structure; Nylons; Psoriasis; Pyrroles; Uveitis | 2020 |
Tofacitinib in psoriatic arthritis patients: skin signs and symptoms and health-related quality of life from two randomized phase 3 studies.
Topics: Adult; Arthritis, Psoriatic; Double-Blind Method; Humans; Piperidines; Psoriasis; Pyrimidines; Pyrroles; Quality of Life; Treatment Outcome | 2020 |
Identification of
Topics: Animals; Dogs; Drug Design; Humans; Models, Molecular; NF-kappaB-Inducing Kinase; Protein Conformation; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Psoriasis; Pyrimidines; Pyrroles; Rats; Structure-Activity Relationship | 2020 |
Successful therapy of palmoplantar pustulosis with tofacitinib-Report on three cases.
Topics: Humans; Piperidines; Psoriasis; Pyrimidines; Pyrroles | 2020 |
Lipid Profiles in Patients With Ulcerative Colitis Receiving Tofacitinib-Implications for Cardiovascular Risk and Patient Management.
Topics: Arthritis, Rheumatoid; Cardiovascular Diseases; Cholesterol; Clinical Trials, Phase III as Topic; Colitis, Ulcerative; Heart Disease Risk Factors; Humans; Inflammation; Lipids; Lipoproteins, HDL; Lipoproteins, LDL; Piperidines; Protein Kinase Inhibitors; Psoriasis; Pyrimidines; Pyrroles; Risk Factors; Treatment Outcome | 2021 |
Lessons from tofacitinib in patients with cardiovascular risk factors: increased pulmonary embolism or isolated (thrombotic) pulmonary occlusion rates?
Topics: Arthritis, Psoriatic; Arthritis, Rheumatoid; Humans; Incidence; Piperidines; Psoriasis; Pulmonary Embolism; Pyrimidines; Pyrroles | 2020 |
Herpes zoster in psoriasis patients treated with tofacitinib.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Asian People; Biological Products; Etanercept; Female; Herpes Zoster; Hospitalization; Humans; Immunosuppressive Agents; Incidence; Male; Middle Aged; Piperidines; Proportional Hazards Models; Psoriasis; Pyrimidines; Pyrroles; Risk Factors; Young Adult | 2017 |
T-cell-mediated immune response to pneumococcal conjugate vaccine (PCV-13) and tetanus toxoid vaccine in patients with moderate-to-severe psoriasis during tofacitinib treatment.
Topics: Adult; Aged; Cohort Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Immunity, Cellular; Male; Middle Aged; Piperidines; Pneumococcal Vaccines; Prospective Studies; Protein Kinase Inhibitors; Psoriasis; Pyrimidines; Pyrroles; Sensitivity and Specificity; Severity of Illness Index; T-Lymphocytes; Tetanus Toxoid; Vaccination; Vaccines, Conjugate; Young Adult | 2018 |
Validation of the Itch Severity Item as a Measurement Tool for Pruritus in Patients with Psoriasis: Results from a Phase 3 Tofacitinib Program.
Topics: Antipruritics; Clinical Trials, Phase III as Topic; Humans; Piperidines; Predictive Value of Tests; Pruritus; Psoriasis; Psychometrics; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Remission Induction; Reproducibility of Results; Severity of Illness Index; Surveys and Questionnaires; Time Factors; Treatment Outcome | 2018 |
Topical Sunitinib ointment alleviates Psoriasis-like inflammation by inhibiting the proliferation and apoptosis of keratinocytes.
Topics: Administration, Topical; Animals; Apoptosis; Cell Line; Cell Proliferation; Down-Regulation; Gene Expression Regulation; Indoles; Inflammation; Keratinocytes; Male; Mice; Organ Size; Phosphoproteins; Psoriasis; Pyrroles; Signal Transduction; STAT3 Transcription Factor; Sunitinib; Vascular Endothelial Growth Factor A | 2018 |
Tofacitinib Represses the Janus Kinase-Signal Transducer and Activators of Transcription Signalling Pathway in Keratinocytes.
Topics: Case-Control Studies; Cells, Cultured; Down-Regulation; Early Growth Response Protein 1; Humans; Interleukin-22; Interleukins; Janus Kinases; Keratinocytes; Piperidines; Protein Kinase Inhibitors; Psoriasis; Pyrimidines; Pyrroles; S100 Calcium Binding Protein A7; Signal Transduction; STAT Transcription Factors | 2018 |
Pharmacokinetic Characteristics of Tofacitinib in Adult Patients With Moderate to Severe Chronic Plaque Psoriasis.
Topics: Adult; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dose-Response Relationship, Drug; Female; Humans; Inactivation, Metabolic; Janus Kinase Inhibitors; Male; Models, Biological; Piperidines; Psoriasis; Pyrimidines; Pyrroles; Severity of Illness Index; Tissue Distribution | 2018 |
Benefit-risk profile of tofacitinib in patients with moderate-to-severe chronic plaque psoriasis: pooled analysis across six clinical trials.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Chronic Disease; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Piperidines; Protein Kinase Inhibitors; Psoriasis; Pyrimidines; Pyrroles; Quality of Life; Randomized Controlled Trials as Topic; Risk Assessment; Severity of Illness Index; Young Adult | 2019 |
Long-term safety data for tofacitinib, an oral Janus kinase inhibitor, for the treatment for psoriasis.
Topics: Humans; Janus Kinase Inhibitors; Piperidines; Psoriasis; Pyrimidines; Pyrroles | 2018 |
JAK1/3 inhibition preserves epidermal morphology in full-thickness 3D skin models of atopic dermatitis and psoriasis.
Topics: Cell Proliferation; Computer Simulation; Dermatitis, Atopic; Filaggrin Proteins; Humans; Imaging, Three-Dimensional; Intermediate Filament Proteins; Janus Kinase 1; Keratinocytes; Piperidines; Psoriasis; Pyrimidines; Pyrroles; Sensitivity and Specificity; STAT6 Transcription Factor | 2019 |
Antipruritic Effects of Janus Kinase Inhibitor Tofacitinib in a Mouse Model of Psoriasis.
Topics: Animals; Antipruritics; Behavior, Animal; Disease Models, Animal; Imiquimod; Interleukin-22; Interleukin-23; Interleukins; Janus Kinase Inhibitors; Male; Mice, Inbred C57BL; Nerve Fibers; Piperidines; Pruritus; Psoriasis; Pyrimidines; Pyrroles; Skin | 2019 |
Tofacitinib: a new oral Janus kinase inhibitor for psoriasis.
Topics: Humans; Janus Kinase Inhibitors; Piperidines; Psoriasis; Pyrimidines; Pyrroles | 2019 |
A multi-item Physician Global Assessment scale to assess psoriasis disease severity: validation based on four phase III tofacitinib studies.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Clinical Trials, Phase III as Topic; Female; Humans; Janus Kinase Inhibitors; Male; Middle Aged; Piperidines; Psoriasis; Pyrimidines; Pyrroles; Quality of Life; Reproducibility of Results; Severity of Illness Index; Skin; Treatment Outcome; Young Adult | 2019 |
Tofacitinib for the treatment of recalcitrant palmoplantar pustulosis: A case report.
Topics: Female; Humans; Middle Aged; Piperidines; Protein Kinase Inhibitors; Psoriasis; Pyrimidines; Pyrroles | 2020 |
Tofacitinib and other kinase inhibitors in the treatment of psoriasis.
Topics: Humans; Piperidines; Protein Kinase Inhibitors; Psoriasis; Pyrimidines; Pyrroles | 2013 |
Systemics to topicals in psoriasis: the unfilled need.
Topics: Dermatologic Agents; Female; Humans; Male; Piperidines; Protein Kinase Inhibitors; Psoriasis; Pyrimidines; Pyrroles | 2013 |
Targeting PKC in human T cells using sotrastaurin (AEB071) preserves regulatory T cells and prevents IL-17 production.
Topics: Biopsy; CD28 Antigens; Cell Proliferation; Coculture Techniques; Cytokines; Forkhead Transcription Factors; Homeostasis; Humans; Interferon-gamma; Interleukin-17; Interleukin-1beta; Interleukin-2 Receptor alpha Subunit; Lymphocyte Activation; Protein Kinase C; Psoriasis; Pyrroles; Quinazolines; Skin; T-Lymphocytes, Helper-Inducer; T-Lymphocytes, Regulatory | 2014 |
Dramatic effect of sunitinib with rapid but transient improvement for psoriasis in a patient with metastatic renal carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Psoriasis; Pyrroles; Remission Induction; Sunitinib | 2013 |
Killing two birds with one stone: oral tofacitinib reverses alopecia universalis in a patient with plaque psoriasis.
Topics: Adult; Alopecia; Dose-Response Relationship, Drug; Humans; Male; Piperidines; Protein Kinase Inhibitors; Psoriasis; Pyrimidines; Pyrroles; Treatment Outcome | 2014 |
Transforming growth factor-β1 mediates psoriasis-like lesions via a Smad3-dependent mechanism in mice.
Topics: Animals; Disease Models, Animal; Humans; Interleukin-17; Interleukin-23; Interleukin-6; Isoquinolines; Mice; Mice, Transgenic; Ointments; Psoriasis; Pyridines; Pyrroles; Real-Time Polymerase Chain Reaction; Signal Transduction; Skin; Smad3 Protein; Transforming Growth Factor beta1 | 2014 |
Modulation of LXR-α and the effector genes by Ascorbic acid and Statins in psoriatic keratinocytes.
Topics: Adolescent; Adult; Antioxidants; Ascorbic Acid; Atorvastatin; Female; Gene Expression Regulation; Heptanoic Acids; Humans; Hydroxycholesterols; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Keratinocytes; Liver X Receptors; Male; Orphan Nuclear Receptors; Psoriasis; Pyrroles | 2014 |
Two birds that exclude each other: the Renbök phenomenon.
Topics: Alopecia; Humans; Male; Piperidines; Psoriasis; Pyrimidines; Pyrroles | 2015 |
Tofacitinib, a novel JAK3 inhibitor, as a potential cause of distal symmetric polyneuropathy.
Topics: Adult; Humans; Male; Piperidines; Psoriasis; Pyrimidines; Pyrroles | 2016 |
Oral tofacitinib for psoriasis: what happens with interrupted treatment?
Topics: Dermatologic Agents; Female; Humans; Male; Piperidines; Protein Kinase Inhibitors; Psoriasis; Pyrimidines; Pyrroles | 2015 |
Do we need more psoriasis therapies?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Female; Humans; Immunoglobulin G; Male; Piperidines; Protein Kinase Inhibitors; Psoriasis; Pyrimidines; Pyrroles; Receptors, Tumor Necrosis Factor | 2015 |
Pulmonary Cryptococcosis in the Setting of Tofacitinib Therapy for Psoriasis.
Topics: Aged; Cryptococcosis; Humans; Lung Diseases; Male; Piperidines; Protein Kinase Inhibitors; Psoriasis; Pyrimidines; Pyrroles | 2015 |
Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: Long-term efficacy and safety results from 2 randomized phase-III studies and 1 open-label long-term extension study.
Topics: Administration, Oral; Adult; Aged; Chronic Disease; Clinical Trials, Phase III as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Janus Kinases; Male; Middle Aged; Patient Safety; Piperidines; Protein Kinase Inhibitors; Psoriasis; Pyrimidines; Pyrroles; Quality of Life; Randomized Controlled Trials as Topic; Severity of Illness Index; Time Factors; Treatment Outcome; Young Adult | 2016 |
Pregnancy Outcomes in the Tofacitinib Safety Databases for Rheumatoid Arthritis and Psoriasis.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Databases, Factual; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Infant, Newborn; Methotrexate; Piperidines; Pregnancy; Pregnancy Outcome; Protein Kinase Inhibitors; Psoriasis; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Young Adult | 2016 |
Effects of tofacitinib on cardiovascular risk factors and cardiovascular outcomes based on phase III and long-term extension data in patients with plaque psoriasis.
Topics: Adult; Blood Pressure; C-Reactive Protein; Cardiovascular Diseases; Cholesterol; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Comorbidity; Dyslipidemias; Female; Glycated Hemoglobin; Humans; Male; Metabolic Syndrome; Middle Aged; Piperidines; Protein Kinase Inhibitors; Psoriasis; Pyrimidines; Pyrroles; Risk Factors; Treatment Outcome; Triglycerides | 2016 |
Small Molecules for Psoriasis.
Topics: Acitretin; Administration, Oral; Dermatologic Agents; Evidence-Based Medicine; Humans; Piperidines; Psoriasis; PUVA Therapy; Pyrimidines; Pyrroles; Treatment Outcome | 2016 |
Update on TNF Inhibitors.
Topics: Adalimumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Arthritis, Psoriatic; Cardiovascular Diseases; Certolizumab Pegol; Clinical Trials as Topic; Clinical Trials, Phase III as Topic; Dermatologic Agents; Etanercept; Humans; Infliximab; Piperidines; Psoriasis; Pyrimidines; Pyrroles; Treatment Outcome; Tumor Necrosis Factor-alpha; Ustekinumab | 2016 |
Successful treatment of palmoplantar pustulosis with rheumatoid arthritis, with tofacitinib: Impact of this JAK inhibitor on T-cell differentiation.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Female; Humans; Janus Kinase Inhibitors; Middle Aged; Piperidines; Psoriasis; Pyrimidines; Pyrroles; Treatment Outcome | 2016 |
Metastatic adamantinoma responds to treatment with receptor tyrosine kinase inhibitor.
Topics: Accidents, Traffic; Adamantinoma; Antineoplastic Agents; Appendicitis; Enzyme Inhibitors; Foot; Fractures, Bone; Humans; Immunohistochemistry; Indoles; Lung Neoplasms; Male; Middle Aged; Psoriasis; Pyrroles; Receptor Protein-Tyrosine Kinases; Smoking; Sunitinib; Tomography, X-Ray Computed; Vitamin B 12 Deficiency | 2010 |
Sorafenib-associated remission of psoriasis in hypernephroma: case report.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Male; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Psoriasis; Pyridines; Pyrroles; Retreatment; Sorafenib; Sunitinib; Treatment Outcome | 2010 |
Improvement of psoriasis during sunitinib therapy for renal cell carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Psoriasis; Pyrroles; Sunitinib | 2010 |
Structure-activity relationship and pharmacokinetic studies of sotrastaurin (AEB071), a promising novel medicine for prevention of graft rejection and treatment of psoriasis.
Topics: Animals; Cells, Cultured; Graft Rejection; Humans; Lymphocyte Activation; Macaca fascicularis; Mice; Mice, Inbred BALB C; Protein Kinase C; Protein Kinase Inhibitors; Psoriasis; Pyrroles; Quinazolines; Rats; Structure-Activity Relationship; Tissue Distribution | 2011 |
PKCθ: a new target for selective immunosuppression.
Topics: Animals; Graft Rejection; Graft vs Host Disease; Humans; Immunosuppression Therapy; Isoenzymes; Mice; Mice, Knockout; Molecular Targeted Therapy; NF-kappa B; Protein Kinase C; Protein Kinase C-theta; Protein Kinase Inhibitors; Psoriasis; Pyrroles; Quinazolines; Signal Transduction; T-Lymphocytes | 2012 |
Therapeutics: Silencing psoriasis.
Topics: Alefacept; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Clinical Trials as Topic; Dermatologic Agents; Humans; Interleukin-17; Piperidines; Psoriasis; Pyrimidines; Pyrroles; Recombinant Fusion Proteins; Thalidomide; Ustekinumab | 2012 |
SU-011248, a vascular endothelial growth factor receptor-tyrosine kinase inhibitor, controls chronic psoriasis.
Topics: Angiogenesis Inhibitors; Chronic Disease; Humans; Indoles; Male; Middle Aged; Psoriasis; Pyrroles; Remission Induction; Sunitinib; Vascular Endothelial Growth Factor Receptor-2 | 2007 |
Regeneration of human epidermis on acellular dermis is impeded by small-molecule inhibitors of EGF receptor tyrosine kinase.
Topics: Cell Proliferation; Cells, Cultured; Dermis; Dose-Response Relationship, Drug; Enzyme Inhibitors; Epidermal Growth Factor; Epidermis; ErbB Receptors; Humans; Keratinocytes; Models, Biological; Organ Culture Techniques; Protein-Tyrosine Kinases; Psoriasis; Pyrimidines; Pyrroles; Receptor, ErbB-2; Regeneration | 2008 |
Severe psoriasis and tolmetin sodium therapy.
Topics: Adolescent; Adult; Child; Child, Preschool; Humans; Male; Psoriasis; Pyrroles; Tolmetin | 1980 |
[Dermatologic topical treatment. 5. Psoriasis].
Topics: Anthracenes; Humans; Methotrexate; Ointments; Psoriasis; Pyrroles; Steroids; Ultraviolet Therapy | 1971 |